

ΣΥΝΟΠΤΙΚΟ ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ:

Ιωάννης Νιώπας, BPharm, BChem, BBA, PhD

Καθηγητής Πρώτης Βαθμίδας

Τηλ.: 2310 997663; E-mail: niopas@pharm.auth.gr

Σπουδές:

- 1982:** Διδακτορικό (PhD), Σχολή Φαρμακευτικών Σπουδών,
Πανεπιστήμιο Strathclyde, Glasgow, U.K.
- 1972:** Πτυχίο Φαρμακευτικής, Τμήμα Φαρμακευτικής, Α.Π.Θ.
- 1978:** Πτυχίο Χημείας, Τμήμα Χημείας, Α.Π.Θ.
- 1998:** Πτυχίο Οργάνωσης και Διοίκησης Επιχειρήσεων,
Τμήμα Οργάνωσης και Διοίκησης Επιχειρήσεων,
Πανεπιστήμιο Μακεδονίας

Ακαδημαϊκές Θέσεις:

- 1986-1987 Μεταδιδακτορικός Ερευνητής στην Κλινική Φαρμακοκινητική
(Καθηγητής Malcolm Rowland), Σχολή Φαρμακευτικών
Επιστημών, Πανεπιστήμιο Manchester, U.K.
- 1993 Μεταδιδακτορικός Ερευνητής στην Τοξικολογία και
Αλληλεπιδράσεις Φαρμάκων (Καθηγητής John Caldwell),
Τμήμα Φαρμακολογίας & Τοξικολογίας, St. Mary's Hospital
Medical School, Imperial College, London, U.K.
- 1976-1979 Βοηθός στη Φαρμακευτική Χημεία, Τμήμα Φαρμακευτικής,
Α.Π.Θ.
- 1983-1986 Λέκτορας στη Φαρμακευτική Χημεία, Τμήμα Φαρμακευτικής,
Α.Π.Θ.
- 1986-1991 Λέκτορας στη Φαρμακολογία και Κλινική Φαρμακοκινητική,
Τμήμα Φαρμακευτικής, Α.Π.Θ.
- 1991-2004 Επίκουρος Καθηγητής στη Φαρμακολογία και Κλινική
Φαρμακοκινητική, Τμήμα Φαρμακευτικής, Α.Π.Θ.
- 2005-2010 Αναπληρωτής Καθηγητής στη Φαρμακολογία και Κλινική
Φαρμακοκινητική, Τμήμα Φαρμακευτικής, Α.Π.Θ.

2010 - Καθηγητής Πρώτης Βαθμίδας στην Κλινική Φαρμακευτική και Φαρμακοκινητική, Τμήμα Φαρμακευτικής, Α.Π.Θ.

Ερευνητικά Ενδιαφέροντα:

Κλινική Φαρμακοκινητική
Μελέτες Βιοδιαθεσιμότητας/Βιοϊσοδυναμίας
Αλληλεπιδράσεις Φαρμάκων
Μεταβολισμός Φαρμάκων
Ανάπτυξη και Επικύρωση Βιοαναλυτικών Μεθόδων

Εκπαιδευτικό Έργο:

Τοξικολογία (για προπτυχιακούς φοιτητές)
Κλινική Φαρμακοκινητική (για προπτυχιακούς φοιτητές)
Κλινική Φαρμακολογία και Θεραπευτική (για προπτυχιακούς φοιτητές)
Φαρμακοκινητική (για μεταπτυχιακούς φοιτητές)
Φυτοθεραπεία (για μεταπτυχιακούς φοιτητές)

Δημοσιεύσεις:

1. Spanakis M, **Niopas I.** (2013) “Determination of atenolol in human plasma by HPLC with fluorescence detection: Validation and application in a pharmacokinetic study”, *J Chromatogr Sci*, **51**: 128-132.
2. Spanakis M, Vizirianakis IS, Batzias G, **Niopas I.** (2013) “Pharmacokinetic Interaction between Losartan and *Rhodiola rosea* in Rabbits”, *Pharmacology*, **91**: 112-116.
3. Touraki M, Niopas I, Karagiannis V. (2012) “Treatment of vibriosis in European sea bass larvae, *Dicentrarchus labrax* L., with oxolinic acid administered by bath or through medicated nauplii of *Artemia franciscana* (Kellogg): Efficacy and residual kinetics”, *J Fish Dis*, **35**: 513-522.
4. Touraki M, **Niopas I.** (2010) “Bioencapsulation and pharmacokinetic study of oxolinic acid in rotifers (*Brachionus plicatilis*), *Artemia franciscana* nauplii and metanauplii”, *Aquaculture Res*, *in press*.
5. Spanakis M, **Niopas I.** (2010) “GC-MS simultaneous determination of enalapril and enalaprilat in human plasma: Application to a clinical pharmacokinetic study”, *Chromatographia*, **72**: 957-962.
6. Touraki M, **Niopas I,** Ladoukakis E, Karagiannis V. (2010) “Efficacy of flumequine administered by bath or through medicated nauplii of *Artemia franciscana* (L.) in the treatment of vibriosis in sea bass larvae”, *Aquaculture*, **306**: 146-152.
7. Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, Spanakis M, Teperikidis L, **Niopas I.** (2010) “Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece”, *Pharm World Sci*, **32**: 187-193.
8. Kanaze FI, Kokkalou E, **Niopas I,** Barmplexis P, Georgarakis E, Bikiaris D. (2010) “Dissolution rate and stability study of flavanone aglycones, naringenin and hesperetin, by drug delivery systems based on polyvinylpyrrolidone (PVP) nanodispersions”, *Drug Dev Ind Pharm*, **36**: 292-301.
9. Kanaze FI, Termentzi A, Gabrieli C, **Niopas I,** Georgarakis M, Kokkalou E. (2009) “The phytochemical analysis and antioxidant activity assessment of orange peel (*Citrus sinensis*) cultivated in Greece-Crete indicates a new commercial source of hesperidin”, *Biomed Chromatogr*, **23**: 239-249.
10. Spanakis M, Kasmias S, **Niopas I.** (2009) “Simultaneous determination of the flavonoid aglycones diosmetin and hesperetin in human plasma and urine by a validated GC/MS method: In vivo metabolic reduction of diosmetin to hesperetin”, *Biomed Chromatogr*, **23**: 124-131.

11. Kimiskidis V, Spanakis M, **Niopas I**, Kazis D, Gabrieli C, Kanaze FI, Divanoglou D: (2007) Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study”, *J Pharm Biomed Anal*, **43**: 763-768.
12. Kanaze FI, Bounartzi MI, Georgarakis M, **Niopas I**: (2007) “Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects” *J Clin Nutr*, **61**: 472-477.
13. Kanaze FI, Kokkalou E, **Niopas I**, Georgarakis M, Stergiou A, Bikiaris D: (2006) “Thermal analysis study of flavonoid solid dispersions having enhanced solubility”, *J Therm Anal Calor*, **83**: 283-290.
14. Kanaze FI, Kokkalou E, **Niopas I**, Georgarakis M, Stergiou A, Bikiaris D: (2006) “Dissolution enhancement of flavonoids by solid dispersion in PVP and PEG matrices: A comparative study”, *J Appl Polym Sci*, **102**: 460-471.
15. Kimiskidis VK, **Niopas I**, Firinidis PD, Kanaze FI, Gabrieli C, Kazis D, Papagiannopoulos S, Kazis A: (2005) “Frequency distribution of dextromethorphan O-demethylation in a Greek population”, *Int J Clin Pharmacol Ther*, **43**: 150-153.
16. Bozikas VP, **Niopas I**, Kafantari A, Kanaze FI, Gabrieli C, Melissidis P, Gamvrula K, Fokas K, Karavatos A: (2005) “No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia”, *Prog Neuropsychopharmacol Biol Psychiatry*, **29**: 1-6.
17. Kanaze FI, Kokkalou E, Georgarakis M, **Niopas I**: (2004) “A validated solid-phase extraction HPLC method for the simultaneous determination of the citrus flavanone aglycones hesperetin and naringenin in urine”, *J Pharm Biomed Anal*, **36**: 175-181.
18. Kanaze FI, Bounartzi MI, **Niopas I**: (2004) “A validated HPLC determination of the flavone aglycone diosmetin in human plasma”, *Biomed Chromatogr*, **18**: 800-804.
19. **Niopas I**, Daftsios AC, Nicolaidis N: (2004) “Evaluation of bioequivalence of two tablet formulations of enalapril/hydrochlorothiazide after single oral administration to healthy volunteers”, *Arzneim Forsch / Drug Res*, **35**: 160-165.
20. Bozikas VP, Papakosta M, **Niopas I**, Kafantari A, Mirtsou-Fidani V, Karavatos AD: (2004) “Smoking impact on *CYP1A2* activity in a group of patients with schizophrenia”, *Eur Neuropsychopharmacol*, **14**: 39-44.
21. Kanaze FI, Kokkalou E, Georgarakis M, **Niopas I**: (2004) “A validated high-performance liquid chromatographic method utilizing solid-phase extraction for the simultaneous determination of naringenin and hesperetin in human plasma”,

- J Chromatogr B*, **801**: 363-367.
22. Kanaze FI, Gabrieli C, Kokkalou E, Georgarakis M, **Niopas I**: (2003) “Simultaneous reversed-phase high-performance liquid chromatographic method for the determination of diosmin, hesperidin and naringin in different citrus fruit juices and pharmaceutical formulations”, *J Pharm Biomed Anal*, **33**: 243-249.
 23. **Niopas I**, Daftsios AC: (2003) “Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and adaptation to pharmacokinetic studies”, *J Pharm Biomed Anal*, **32**: 1213-1218.
 24. **Niopas I**, Daftsios AC, Nicolaidis N: (2003) “Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers”, *Int J Clin Pharmacol Ther*, **41**: 226-230.
 25. **Niopas I**, Daftsios AC: (2002) “A validated high-performance liquid chromatographic method for the determination of glibenclamide in human plasma and its application to pharmacokinetic studies”, *J Pharm Biomed Anal*, **28**: 653-657.
 26. **Niopas I**, Daftsios AC: (2002) “A validated HPLC method for the determination of hydrochlorothiazide in human plasma and its application in pharmacokinetic study”, *J Liq Chromatogr Rel Technol*, **25**: 487-494.
 27. **Niopas I**, Daftsios AC, Nikolaidis N: (2002) “Evaluation of Bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers», *Arzneim Forsch / Drug Res*, **52**: 182-186.
 28. **Niopas I**, Daftsios AC: (2001) “Determination of clarithromycin in human plasma by HPLC with electrochemical detection: validation and application in pharmacokinetic study”, *Biomed Chromatogr*, **15**: 507-508.
 29. **Niopas I**, Daftsios AC: (2001) “A validated gas chromatographic method for the determination of isosorbide-5-mononitrate in human plasma and its application to pharmacokinetic studies”, *Pharmazie*, **50**: 589-590.
 30. **Niopas I**, Daftsios AC: (2001) “Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies”, *J Chromatogr B Biomed Appl*, **759**: 179-183.
 31. **Niopas I**, Daftsios AC, Nikolaidis N (2001) “Human bioequivalence study of clarithromycin from two tablet formulations after single oral administration”, *Clin Drug Invest*, **21**: 211-217.
 32. **Niopas I**, Daftsios AC, Nikolaidis N: (2001) “Relative bioavailability of two

- isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects”, *Int J Clin Pharmacol Ther*, **39**: 224-228.
33. Kimiskidis VK, Mirtsou-Fidani V, Papaioannidou PG, **Niopas I**, Georgiadis G, Constantinidis TC, Kazis AD: (1999) “A phase I clinical trial of dextromethorphan in intractable partial epilepsy”, *Methods Find Exp Clin Pharmacol*, **21**: 673-678.
 34. **Niopas I**, Daftsios AC, Xanthakis I, Nikolaidis N: (1999) “Relative bioavailability study of two nifedipine tablet formulations in healthy male volunteers”, *Int J Clin Pharmacol Ther*, **38**: 309-314.
 35. **Niopas I**, Daftsios AC, Xanthakis I, Nikolaidis N, Njau SN: (1999) “Bioequivalence of two tablet formulations of atenolol after single oral administration in healthy volunteers”, *Arzneim Forschung / Drug Res*, **50**: 243-247.
 36. **Niopas I**, Holt L, Aarons L, Rowland M: (1999) “The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans“, *Eur J Clin Pharmacol*, **55**: 399-404.
 37. Touraki M, **Niopas I**, Kastritsis C: (1999) “Bioaccumulation of trimethoprim, sulfamethoxazole and N-acetylsulfamethoxazole in *Artemia nauplii* and residual kinetics in seabass larvae after repeated oral dosing of medicated nauplii”, *Aquaculture*, **175**: 15-30.
 38. Bosabalidis A, Gabrieli C, **Niopas I**: (1998) “Flavone aglycones in glandular hairs of *Origanum x intercedens*”, *Phytochemistry*, **49**: 1549-1553.
 39. Ktistis G, **Niopas I**: (1998) “A study of the in-vitro percutaneous absorption of propranolol from disperse systems”, *J Pharm Pharmacol*, **50**: 413-418.
 40. Kimiskidis VK, Kazis AD, **Niopas I**: (1996) “Simultaneous determination of dextromethorphan and dextrorphan in human plasma, urine and cerebrospinal fluid by HPLC with fluorescence detection”, *J Liq Chrom & Rel Technol*, **19**: 1267-1275.
 41. Kazis A, Kimiskidis V, **Niopas I**: (1996) “Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients”, *Acta Neurol Scand*, **93**: 94-98.
 42. Mamzoridi K, Kasteridou N, Peonides A, **Niopas I**: (1996) “Pharmacokinetics of cefixime in children with urinary tract infections after a single oral dose”, *Pharmacol Toxicol*, **78**: 417-420.
 43. Chaisuksant R, **Niopas I**, Voulgaropoulos A, Mellidis AS, Papageorgiou VP: (1995) “Analysis of some isohexenylnaphthazarins by reversed-phase HPLC”, *Pharmazie*, **50**: 363.
 44. **Niopas I**, Georganakis M, Sidi-Frangandrea V, Chrisanthopoulos C, Liara E: (1995) “Pharmacokinetics of tolfenamic acid in pediatric patients after single oral Dose“, *Eur J Drug Metab Pharmacokinet*, **20**: 293-296.

45. **Niopas I**, Georgarakis M: (1995) "Determination of tolfenamic acid in human plasma by HPLC", *J Liq Chromatogr*, **18**: 2675-2682.
46. Caldwell J, Bounds SVJ, Grubb NG, **Niopas I**: (1995) "Use of isotopically labelled pseudoracemates for the study of chiral drugs", *Synthesis and Applications of Isotopically Labeled Compounds*, Allen J, Ed, John Wiley & Sons Ltd, London, pp. 811-818.
47. **Niopas I**, Mamzoridi K: (1994) "Determination of Indomethacin and Mefenamic Acid in Plasma by High-Performance Liquid Chromatography", *J Chromatogr B*, **656**: 447-450.
48. Pappas IS, **Niopas I**, Tsiftoglou AS: (1992) "Ureido Derivatives of Pyridine: A Class of Potent Inducers of Murine Erythroleukemia Cell Differentiation", *Anti-Cancer Drug Design*, **7**: 153-161.
49. **Niopas I**, Smail GA: (1992) "Enamine Reactions of 1,3-Dioxo-5H-imidazo[1,5-b]-Isoquinolines", *Pharmazie*, **47**: 189-191.
50. **Niopas I**, Toon S, Rowland M: (1991) "Further Insight into the Stereoselective Interaction between Warfarin and Cimetidine in Man", *Br J Clin Pharmacol*, **32**: 508-511.
51. **Niopas I**, Smail GA: (1991) "Reactions of 1,3-Dioxoimidazo[1,5-b]isoquinolinium Bromides with Nucleophiles", *J Chem Soc Perkin Trans 1*, 119-125.
52. **Niopas I**, Smail GA: (1991) "Reactions of 1,3-Dioxo-5H,10H-imidazo[1,5-b]-isoquinolines with Bromine", *J Chem Soc Perkin Trans 1*, 113-117.
53. Avgoustakis K, **Niopas I**: (1991) "Dissolution and Bioavailability Evaluation of Three Brands of Paracetamol Tablets", *Review of Clinical Pharmacology and Pharmacokinetics, International Edition*, **5**: 58-61.
54. Tsiftoglou AS, Pappas IS, **Niopas I**: (1991) "Structural, Cellular and Pharmacological Implications of Neoplastic Cell Differentiation Induced by Ureido-Derivatives of Pyridine (UDPs)", *Top Mol Organ Eng, 8 (Chem Prop Biomol Syst)*, 189-208.
55. Gabrieli C, Kokkalou E, **Niopas I**: (1990) "Anti-Inflammatory Activity of a Novel Glucosylated Acylflavone from *Sideritis raeseri*", *Scientia Pharmaceutica*, **58**: 395-397.
56. Albanoudi N, Gabrieli C, **Niopas I**: (1990) "Anti-Inflammatory Activity of N2-Substituted 10,10a-dihydroimidazo[1,5-b]isoquinoline-1,3(2H,5H)-diones", *Scientia Pharmaceutica*, **58**: 259-262.
57. **Niopas I**, Smail GA: (1990) "N-Substituted Tricyclic Isoquinoline Hydantoins", *Collect Czech Chem Commun*, **55**: 540-545.
58. Weir EC, **Niopas I**, Smail GA: (1989) "Tricyclic Hydantoins and Thiohydantoins

of Phenylalanine”, *Chimika Chronika*, **18**: 3-17.